Details

Autor(en) / Beteiligte

• Keppler-Hafkemeyer, Andrea
• Greil, Christine
• Wratil, Paul R
• Shoumariyeh, Khalid
• Stern, Marcel
• Hafkemeyer, Annika
• Ashok, Driti
• Hollaus, Alexandra
• Lupoli, Gaia
• Priller, Alina
• Bischof, Marie L
• Ihorst, Gabriele
• Engelhardt, Monika
• Marks, Reinhard
• Finke, Jürgen
• Bertrand, Hannah
• Dächert, Christopher
• Muenchhoff, Maximilian
• Badell, Irina
• Emmerich, Florian
• Halder, Hridi
• Spaeth, Patricia M
• Knolle, Percy A
• Protzer, Ulrike
• von Bergwelt-Baildon, Michael
• Duyster, Justus
• Hartmann, Tanja N
• Moosmann, Andreas
• Keppler, Oliver T

Titel

Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma

Ist Teil von

• Nature cancer, 2023-01, Vol.4 (1), p.81

Ort / Verlag

England

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Individuals with hematologic malignancies are at increased risk for severe coronavirus disease 2019 (COVID-19), yet profound analyses of COVID-19 vaccine-induced immunity are scarce. Here we present an observational study with expanded methodological analysis of a longitudinal, primarily BNT162b2 mRNA-vaccinated cohort of 60 infection-naive individuals with B cell lymphomas and multiple myeloma. We show that many of these individuals, despite markedly lower anti-spike IgG titers, rapidly develop potent infection neutralization capacities against several severe acute respiratory syndrome coronavirus 2 variants of concern (VoCs). The observed increased neutralization capacity per anti-spike antibody unit was paralleled by an early step increase in antibody avidity between the second and third vaccination. All individuals with hematologic malignancies, including those depleted of B cells and individuals with multiple myeloma, exhibited a robust T cell response to peptides derived from the spike protein of VoCs Delta and Omicron (BA.1). Consistently, breakthrough infections were mainly of mild to moderate severity. We conclude that COVID-19 vaccination can induce broad antiviral immunity including ultrapotent neutralizing antibodies with high avidity in different hematologic malignancies.